AI assistant
Marksans Pharma Ltd. Capital/Financing Update 2024
62142_rns_2024-02-13_c2f9f02b-a444-4fd0-8899-f8c8a67cbeab.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Date: February 13, 2024
Corporate Relation Department Listing Department Dalal Street, Bandra-Kurla Complex, Scrip Code: 524404 Symbol: MARKSANS
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeeboi Towers, Exchange Plaza, C-1, Block-G, Mumbai - 400001. Bandra (East), Mumbai - 400051.
Sub: Statement on Deviation or Variation of funds raised through Preferential Issue of Convertible Warrants.
Dear Sir/Madam,
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDl/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021.
Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended December 31, 2023 is enclosed as "Annexure A".
We request you to take the aforesaid in your records.
Thanking You.
Yours faithfully, For Marksans Pharma Limited
HARSHAVARDH AN PANIGRAHI Digitally signed by HARSHAVARDHAN PANIGRAHI Date: 2024.02.13 17:20:23 +05'30'
Harshavardhan Panigrahi Company Secretary
Encl: As above
Marksans Pharma Ltd.
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road , Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: [email protected] www.marksanspharma.com
| Statement of Deviation / Variation in utilization of funds raised |
|||
|---|---|---|---|
| Name of listed entity | Marksans Pharma Limited | ||
| Mode of Fund Raising | Preferential Issue | ||
| Date of Raising Funds | 20.07.2021& 18.01.2023 | ||
| Amount Raised | Rs. 3 72,39,99,976.00 | ||
| Report filed for Quarter ended | December 31, 2023 | ||
| Monitoring Agency | Not Aoolicable | ||
| Monitoring Airency Name, if aoolicable | Not Aoolicable | ||
| Is there a Deviation I Variation in use of funds raised | No | ||
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was aooroved by the shareholders |
Not Applicable | ||
| If Yes, Date of shareholder Aooroval | Not Applicable | ||
| Explanation for the Deviation / Variation | Not Applicable | ||
| Comments of the Audit Committee after review | No Comments | ||
| Comments or the auditors, if any | No Comments |
Statement of Deviation or Variation for the quarter ended December 31, 2023
| Objects for which funds have been raised and where there has been a deviation, in the followim; table | |||||||
|---|---|---|---|---|---|---|---|
| Original Object | Modified Object, if any |
Original Allocatio nason 18"' January. 2023 InRs. |
Modified allocation , if any |
Funds utilised till 3pt December, 2023 InRs. |
Amount of deviation/ variation for the quarter according to applicable object |
Remarks if any |
|
| of The proceeds the preferential issue are proposed to be used to strengthen the capital base and to enhance Jong term financial resources of the Company in order to fund expansion program of the Company. |
None | Rs. 3,72,39,9 9,976.00 |
None | 1,61,44,17, 056.00 |
- | No deviations |
AnnexureA
Deviation or variation could mean:
offer, etc
- (a) Deviation in the objects or purposes for which thefimds have been raised or
- (b) Deviation in the amount of funds actually wilized as against what was originally disclosed or (c) Change in Terms of a contrac/ referred to in the fund raising document i.e. prospecrus, letter of
Name of Signatory- Harshavardhan Panigrahi Designation - Company Secretary & Compliance Officer
